Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 534,081 | 819,975 | 1,093,991 | 745,767 | 379,543 |
| Marketable Securities | 1,705,482 | 1,615,589 | 1,233,874 | 1,154,315 | 1,329,994 |
| Receivables | 156,533 | 198,571 | 141,064 | 646,587 | 610,626 |
| Inventories | 78,516 | 86,363 | 97,899 | 84,358 | 73,940 |
| TOTAL | $2,589,677 | $2,808,576 | $2,675,362 | $2,725,163 | $2,470,083 |
| Non-Current Assets | |||||
| PPE Net | 504,389 | 501,958 | 484,941 | 470,700 | 464,572 |
| Investments And Advances | 40,889 | 40,891 | 40,890 | 40,890 | 40,725 |
| Other Non-Current Assets | 298,590 | 291,879 | 271,120 | 272,676 | 279,889 |
| TOTAL | $843,868 | $834,728 | $796,951 | $784,266 | $785,186 |
| Total Assets | $3,433,545 | $3,643,304 | $3,472,313 | $3,509,429 | $3,255,269 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 54,916 | 73,426 | 40,048 | 53,079 | 45,381 |
| Accrued Expenses | 355,936 | 395,174 | 388,576 | 341,187 | 280,527 |
| Other current liabilities | 21,983 | 37,079 | 26,376 | 22,876 | 13,660 |
| TOTAL | $605,963 | $695,710 | $610,656 | $554,648 | $494,825 |
| Non-Current Liabilities | |||||
| Long Term Debt | 676,710 | 675,697 | 433,799 | 433,151 | 191,590 |
| Deferred Revenues | 131,838 | 149,483 | 115,044 | 98,144 | 116,340 |
| Other Non-Current Liabilities | 1,592,038 | 1,531,334 | 1,494,842 | 1,465,877 | 1,434,541 |
| TOTAL | $2,426,416 | $2,359,391 | $2,105,764 | $2,101,419 | $1,834,254 |
| Total Liabilities | $3,032,379 | $3,055,101 | $2,716,420 | $2,656,067 | $2,329,079 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 120,814 | 120,211 | 119,601 | 118,848 | 117,545 |
| Common Shares | 1,207 | 1,202 | 1,195 | 1,186 | 1,173 |
| Retained earnings | -5,678,534 | -5,438,193 | -5,179,733 | -4,975,219 | -4,785,660 |
| Other shareholders' equity | -38,065 | -33,259 | -34,230 | -36,081 | -36,717 |
| TOTAL | $401,166 | $588,203 | $755,893 | $853,362 | $926,190 |
| Total Liabilities And Equity | $3,433,545 | $3,643,304 | $3,472,313 | $3,509,429 | $3,255,269 |